Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae

Pneumonia remains the single leading cause of childhood death worldwide. Despite the commercial availability of multiple pneumococcal conjugate vaccines (PCVs), high dosage cost and supply shortages prevent PCV delivery to much of the developing world. The current work presents high-yield pneumococc...

Full description

Bibliographic Details
Main Authors: Allison E.B. Turner, Jonas E. Gerson, Helen Y. So, Daniel J. Krasznai, Adrienne J. St. Hilaire, Donald F. Gerson
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2017-03-01
Series:Synthetic and Systems Biotechnology
Subjects:
PCV
Online Access:http://www.sciencedirect.com/science/article/pii/S2405805X16300436